A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Padsevonil (Primary)
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARISE
- Sponsors UCB Biopharma
- 08 Dec 2020 Results presented at the 74th Annual Meeting of the American Epilepsy Society
- 13 Mar 2020 According to a UCB media release, four hundred and eleven patients were assigned to one of four groups with different dosing regimens.
- 13 Mar 2020 According to a UCB media release, the impact of the ARISE results on the second, ongoing study, UCB0092 (DUET), is currently being evaluated.